TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15204145

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 microg/g ointment twice daily for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Betamethasone 0.1% ointment twice daily for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patient self-assessment using visual analogue scales (VAS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adverse events with calcipotriol
Number of subjects: 31
Study: 11816702

Group type: EXPERIMENTAL
Intervention: danaparoid
Number of subjects: 42

Group type: COMPARATOR
Intervention: dextran 70
Number of subjects: 42
Study: 9648983

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (omeprazole plus clarithromycin and tinidazole for 1 week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (full-dose ranitidine for 3 weeks)
Number of subjects: 38
Study: 9403153

Group type: EXPERIMENTAL
Intervention: Cambridge Contextual Reading Test (CCRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: National Adult Reading Test (NART)
Number of subjects: 30
Study: 2019185

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg qid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (40 mg bid)
Number of subjects: 80
Study: 7046974

Group type: EXPERIMENTAL
Intervention: IV and oral metoclopramide
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 117
Study: 31270220

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 29186633

Group type: EXPERIMENTAL
Intervention: Family-centered intervention program (FCIP)
Number of subjects: 251
Study: 26363164

Group type: EXPERIMENTAL
Intervention: NS+budesonide irrigations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (NS) irrigations
Number of subjects: 50
Study: 23530576

Group type: COMPARATOR
Intervention: Acarbose 50 mg once daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily immediately before meals (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group B)
Number of subjects: 60
Study: 21521342

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen C (10 mg mane/5 mg tarde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen A (20 mg mane/10 mg tarde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen B (10 mg mane/10 mg tarde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All hydrocortisone regimens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen C (10 mg/5 mg)
Number of subjects: 10
Study: 18922087

Group type: EXPERIMENTAL
Intervention: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) for 5 min
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) with NOS inhibitor (L-NMMA, 0.1% solution) administered iontophoretically prior to exposure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with NOS inhibitor (L-NMMA, 0.1% solution) administered to the non-irradiated hand
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-irradiated hand (systemic effect)
Number of subjects: 42
Study: 16217756

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mcg of selenized yeast)
Number of subjects: 598
Study: 12946034

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Aspirin (more than 325 mg per day)
Number of subjects: 1905
Study: 11119197

Group type: EXPERIMENTAL
Intervention: Halothane and IV dexamethasone (n=188)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n=201)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Halothane (n=180)
Number of subjects: 569
Study: 8894061

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MD) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizotypal personality disorder (STP) patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 1824752

Group type: EXPERIMENTAL
Intervention: Back School intervention (exercise and education)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Counseling intervention
Number of subjects: 74
Study: 6132935

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (1/6 or 1/2 gill of vodka, equal to 6.5 or 19.6 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (1/6 or 1/2 gill of vodka)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 mg) + Alcohol (1/6 or 1/2 gill of vodka)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30912231

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (25(OH)D) for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28209298

Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 405
Study: 26435334

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 25218194

Group type: EXPERIMENTAL
Intervention: AERAS-402 (single dose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 22068700

Group type: EXPERIMENTAL
Intervention: Balanced propofol sedation (BPS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard sedation
Number of subjects: 110
Study: 19173175

Group type: EXPERIMENTAL
Intervention: Pre-operative training using the Viv-Arte model based on kinesthetic mobilisation principles
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no pre-operative training)
Number of subjects: 27
Study: 17701875

Group type: EXPERIMENTAL
Intervention: Management of intracerebral hemorrhage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent advances in management (i.e., STICH trial and recombinant factor VII trial)
Number of subjects: 0
Study: 15218298

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 i.v. over 1 h followed by gemcitabine 2,000 mg/m2 biweekly until progression or intolerable toxicity
Number of subjects: 32
Study: 12034152

Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 298

Group type: COMPARATOR
Intervention: MANOVA model
Number of subjects: 298
Study: 9879342

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study: 8602597

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering dietary intervention
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype
Number of subjects: 784
Study: 2913248

Group type: EXPERIMENTAL
Intervention: Lidocaine; lidocaine, diazepam, and meperidine; lidocaine, diazepam, meperidine, and headphone music; lidocaine, diazepam, meperidine, and nitrous oxide; lidocaine, diazepam, meperidine, methohexital, and nitrous oxide; lidocaine and nitrous oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supplemental oxygen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine anesthesia
Number of subjects: 60
Study: 1124050

Group type: EXPERIMENTAL
Intervention: 2 puffs of Sch 1000 administered 6 times
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orciprenalin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31710095

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg twice daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31325288

Group type: EXPERIMENTAL
Intervention: mHealth system for secondary prevention of stroke
Number of subjects: 637
Study: 28365804

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 108

Group type: COMPARATOR
Intervention: TachoComb
Number of subjects: 108
Study: 25190154

Group type: EXPERIMENTAL
Intervention: Cash incentive (CNY 10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cash incentive
Number of subjects: 0
Study: 23343798

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100U in 10 mL) via cystoscopy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 21
Study: 21270188

Group type: EXPERIMENTAL
Intervention: u-healthcare (n = 49)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: self-monitored blood glucose (SMBG) (n = 47)
Number of subjects: 144

Group type: COMPARATOR
Intervention: routine care (control, n = 48)
Number of subjects: 144
Study: 19320570

Group type: EXPERIMENTAL
Intervention: FPV/r100
Number of subjects: 115
Study: 16376562

Group type: EXPERIMENTAL
Intervention: Presence of air in the venous cannula
Number of subjects: 135

Group type: COMPARATOR
Intervention: Absence of retained air in the venous cannula
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Volume of air in the venous cannula
Number of subjects: 135
Study: 14964337

Group type: EXPERIMENTAL
Intervention: Counter irritation applied to the left hand using a submaximal effort tourniquet procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: No counter irritation
Number of subjects: 20
Study: 11524357

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (simple placement of hands without exerting pressure)
Number of subjects: 80
Study: 9250256

Group type: EXPERIMENTAL
Intervention: Pranlukast 337.5 mg b.i.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pranlukast 450 mg b.i.d.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 8502270

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g of oil per day, containing 5 g of eicosapentaenoic and docosahexaenoic acid)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Corn oil (isoenergetic amount containing mainly n-6 fatty acids)
Number of subjects: 145
Study: 3568535

Group type: EXPERIMENTAL
Intervention: Ascorbic acid pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28710873

Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg per day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 26955311

Group type: EXPERIMENTAL
Intervention: Precaine gel
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Benzocaine topical paste
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (no topical anesthetic)
Number of subjects: 83
Study: 25063373

Group type: EXPERIMENTAL
Intervention: Atropine premedication for endotracheal intubation
Number of subjects: 32
Study: 22880545

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention
Number of subjects: 131
Study: 20861587

Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salt (MAS) SPD465
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18555827

Group type: EXPERIMENTAL
Intervention: Full-dose almonds (73 +/- 3 g/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Half-dose almonds
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low saturated fat whole-wheat muffins (control)
Number of subjects: 27
Study: 16139655

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2143
Study: 11976799

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 91
Study: 10430198

Group type: EXPERIMENTAL
Intervention: Routine sphygmomanometric blood pressure recordings
Number of subjects: 121
Study: 8699873

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion (1,200 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 1969870

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (Astemizole and Placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 15
Study: 30362375

Group type: EXPERIMENTAL
Intervention: Lurbinectedin and doxorubicin combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan)
Number of subjects: 0
Study: 27476890

Group type: EXPERIMENTAL
Intervention: Audiovisual information (10-min informational animation)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 82
Study: 25593135

Group type: EXPERIMENTAL
Intervention: Aggressive medical management therapy (AMM)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty and stenting plus aggressive medical therapy (PTAS)
Number of subjects: 451
Study: 23740681

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C carriers)
Number of subjects: 24
Study: 21690475

Group type: EXPERIMENTAL
Intervention: Vaccination with 12MP plus tetanus
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Vaccination with 12MP plus 6MHP
Number of subjects: 167

Group type: COMPARATOR
Intervention: CY pretreatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 167
Study: 17531327

Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lithium (600‐1800 mg/day)
Number of subjects: 140
Study: 16487090

Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) phototherapy + tacalcitol ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (NB-UVB) phototherapy alone
Number of subjects: 32
Study: 14595168

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10861151

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the larynx (L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the trachea-carina (T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the bronchus (B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical application of 4% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous lidocaine 1 mg/kg
Number of subjects: 60
Study: 9202565

Group type: EXPERIMENTAL
Intervention: Intracavernosal self-injection therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: External vacuum device (Osbon ErecAid system)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 50
Study: 1528093

Group type: EXPERIMENTAL
Intervention: 0.4 mg nalbuphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.4 mg morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no additional opioid)
Number of subjects: 60
Study: 2859273

Group type: EXPERIMENTAL
Intervention: Trimipramine 150 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30467711

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 305

Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 305
Study: 28548601

Group type: EXPERIMENTAL
Intervention: Pictured individual with known screening status
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Pictured individual with unknown screening status
Number of subjects: 360

Group type: COMPARATOR
Intervention: No screening status information
Number of subjects: 360
Study: 26119013

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 203
Study: 24301133

Group type: EXPERIMENTAL
Intervention: Commercial weight loss programme (Weight Watchers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 0
Study: 21186108

Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving 3-4 dietary goals
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving 1-2 dietary goals
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Highest VO(2 max) tertile achieving none of the dietary goals
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Lowest VO(2 max) tertile achieving none of the dietary goals
Number of subjects: 1334
Study: 21244763

Group type: EXPERIMENTAL
Intervention: Oral CsA 5 mg/kg/day for two consecutive days/week for 24 weeks
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo for two consecutive days/week for 24 weeks
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Oral CsA 5 mg/kg/day
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 17054446

Group type: EXPERIMENTAL
Intervention: Scheduled telephone calls from a pediatric diabetes educator (bimonthly 15-30 min for 7 months)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no scheduled calls)
Number of subjects: 123
Study: 12626887

Group type: EXPERIMENTAL
Intervention: 40 mg/d prednisone as an adjunct to antiretroviral therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10668714

Group type: EXPERIMENTAL
Intervention: Apomorphine 0.05 mg/kg subcutaneously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9132322

Group type: EXPERIMENTAL
Intervention: Flurbiprofen LAT patches (40 mg, replaced every 12 hours)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Diclofenac sodium tablets (50 mg b.d.)
Number of subjects: 109
Study: 8458364

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and diltiazem
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3741714

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30765198

Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 24

Group type: COMPARATOR
Intervention: PVE
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no recurrence)
Number of subjects: 24
Study: 29193016

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly + TCS
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks + TCS
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo + TCS
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dupilumab + TCS
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: All treatment groups (qw + TCS, q2w + TCS, placebo + TCS)
Number of subjects: 325
Study: 26527564

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 70
Study: 25463825

Group type: EXPERIMENTAL
Intervention: Standard care plus infant massage (Massaged Group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 0
Study: 22248038

Group type: EXPERIMENTAL
Intervention: Flibanserin 50 mg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 20650591

Group type: EXPERIMENTAL
Intervention: Optimal chiral chromatographic method using LC/MS/MS technology for eszopiclone quantitation
Number of subjects: 0
Study: 18946003

Group type: EXPERIMENTAL
Intervention: Intensive nutritional supplementation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard nutritional supplementation
Number of subjects: 116
Study: 17308383

Group type: EXPERIMENTAL
Intervention: EnSite NavX three-dimensional mapping system
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional fluoroscopy-based mapping
Number of subjects: 83
Study: 12679737

Group type: EXPERIMENTAL
Intervention: gemcitabine-amifostine-cisplatin (GAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: gemcitabine-cisplatin (GP)
Number of subjects: 40
Study: 10847237

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 9112355

Group type: EXPERIMENTAL
Intervention: HLA-B2702-derived peptide (7 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 8401617

Group type: EXPERIMENTAL
Intervention: OFL: 400 mg per os (n = 95)
Number of subjects: 191

Group type: COMPARATOR
Intervention: CTRX: 1 g intramuscularly (n = 96)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: OFL
Number of subjects: 191

Group type: COMPARATOR
Intervention: CTRX
Number of subjects: 191
Study: 2947710

Group type: EXPERIMENTAL
Intervention: Folium Sennae administered orally
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (conventional medicine; Cimetidine and Rheum officinale)
Number of subjects: 340
Study: 29263227

Group type: EXPERIMENTAL
Intervention: Simultaneous recording during monaural stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simultaneous recording during binaural stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional sequential recording
Number of subjects: 60
Study: 27570447

Group type: EXPERIMENTAL
Intervention: Evogliptin, 5 mg od for 7 days (EVO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin IR, 1,000 mg bid for 7 days (MET)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of EVO and MET (EVO + MET)
Number of subjects: 36